Tadashi Ikeda

Summary

Affiliation: Keio University
Country: Japan

Publications

  1. ncbi The role of neoadjuvant chemotherapy for breast cancer treatment
    Tadashi Ikeda
    Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Breast Cancer 9:8-14. 2002
  2. ncbi The evolution of primary chemotherapy in breast cancer treatment
    Tadashi Ikeda
    Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160 8582, Japan
    Breast Cancer 11:148-55. 2004
  3. ncbi Recent development of sentinel lymph node biopsy for breast cancer in Japan
    Tadashi Ikeda
    Department of Surgery, Keio University School of Medicine, Tokyo, Japan
    Asian J Surg 27:275-8. 2004
  4. ncbi Overview: current status of breast conserving therapy in Japan
    Tadashi Ikeda
    Department of Surgery, Keio University Hospital, 35 Shinanomachi, Shinjuku, Tokyo 160 8582, Japan
    Biomed Pharmacother 56:182s-186s. 2002
  5. ncbi Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases
    Yoshifumi Komoike
    Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
    Cancer 106:35-41. 2006
  6. ncbi Predictors to assess non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastasis
    Hiromitsu Jinno
    Department of Surgery, Keio University School of Medicine, Tokyo, Japan
    Breast J 14:551-5. 2008
  7. ncbi Stereoscopic scintigraphic imaging of breast cancer sentinel lymph nodes
    Chikako Tanaka
    Department of Radiology, Keio University School of Medicine, Japan
    Breast Cancer 14:92-9. 2007
  8. ncbi Increasing age does not affect efficacy of sentinel lymph node biopsy using smaller-sized technetium-99m tin colloids for breast cancer patients
    Hiromitsu Jinno
    Department of Surgery, Keio University School of Medicine, Shinjuku ku, Tokyo 160, Japan
    Am J Surg 190:51-4. 2005
  9. ncbi [Predictive factors affect the choice of strategy for breast cancer surgery]
    Tadashi Ikeda
    Department of Surgery, Keio University School of Medicine, Tokyo, Japan
    Nippon Geka Gakkai Zasshi 103:799-802. 2002
  10. ncbi [Breast cancer]
    Tadashi Ikeda
    Department of Surgery, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
    Gan To Kagaku Ryoho 29:1509-15. 2002

Detail Information

Publications49

  1. ncbi The role of neoadjuvant chemotherapy for breast cancer treatment
    Tadashi Ikeda
    Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Breast Cancer 9:8-14. 2002
    ..Core needle biopsy should be performed before neoadjuvant chemotherapy to avoid over-treatment. It is essential to develop more effective regimens and stratify patients based on predictive factors...
  2. ncbi The evolution of primary chemotherapy in breast cancer treatment
    Tadashi Ikeda
    Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160 8582, Japan
    Breast Cancer 11:148-55. 2004
    ..This article deals with the history of the evolution of primary chemotherapy, along with a discussion of some relevant issues...
  3. ncbi Recent development of sentinel lymph node biopsy for breast cancer in Japan
    Tadashi Ikeda
    Department of Surgery, Keio University School of Medicine, Tokyo, Japan
    Asian J Surg 27:275-8. 2004
    ..The final decision as to whether SLNB is an adequate substitute for axillary dissection awaits the results of prospective randomized trials...
  4. ncbi Overview: current status of breast conserving therapy in Japan
    Tadashi Ikeda
    Department of Surgery, Keio University Hospital, 35 Shinanomachi, Shinjuku, Tokyo 160 8582, Japan
    Biomed Pharmacother 56:182s-186s. 2002
    ..The current status of breast conserving operations in Japan is reviewed in comparison with their status in Western countries...
  5. ncbi Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases
    Yoshifumi Komoike
    Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, Osaka, Japan
    Cancer 106:35-41. 2006
    ..The purpose of this study was to clarify risk factors of IBTR and the impact of IBTR on development of distant metastases in this ethnic group...
  6. ncbi Predictors to assess non-sentinel lymph node status in breast cancer patients with sentinel lymph node metastasis
    Hiromitsu Jinno
    Department of Surgery, Keio University School of Medicine, Tokyo, Japan
    Breast J 14:551-5. 2008
    ..In breast cancer patients with a positive SLN, lymphatic invasion and the number of tumor-involved SLNs were both independent predictors of non-SLN involvement...
  7. ncbi Stereoscopic scintigraphic imaging of breast cancer sentinel lymph nodes
    Chikako Tanaka
    Department of Radiology, Keio University School of Medicine, Japan
    Breast Cancer 14:92-9. 2007
    ..Conventional planar scintigraphy cannot provide three-dimensional(3D) information for SLN biopsy. We applied stereoscopic imaging to preoperative lymphoscintigraphy to obtain 3D information and evaluated its usefulness...
  8. ncbi Increasing age does not affect efficacy of sentinel lymph node biopsy using smaller-sized technetium-99m tin colloids for breast cancer patients
    Hiromitsu Jinno
    Department of Surgery, Keio University School of Medicine, Shinjuku ku, Tokyo 160, Japan
    Am J Surg 190:51-4. 2005
    ..Increasing age of breast cancer patients was reported to cause not only failure of sentinel lymph node (SLN) identification but also false negative results...
  9. ncbi [Predictive factors affect the choice of strategy for breast cancer surgery]
    Tadashi Ikeda
    Department of Surgery, Keio University School of Medicine, Tokyo, Japan
    Nippon Geka Gakkai Zasshi 103:799-802. 2002
    ..Predictive factors for the effect of radiation therapy should also be taken into account after breast-conserving surgery. It remains to be determined which predictive factors should be considered at which time...
  10. ncbi [Breast cancer]
    Tadashi Ikeda
    Department of Surgery, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
    Gan To Kagaku Ryoho 29:1509-15. 2002
    ..To perform good clinical trials, it is imperative to construct infrastructures including clinical research coordinator, and abolish governmental regulation of the dose of anticancer agents...
  11. ncbi [Adjuvant chemotherapy for breast cancer--a current controversy]
    Hiromitsu Jinno
    Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
    Gan To Kagaku Ryoho 31:176-80. 2004
    ..Dose-dense therapy seems promising but still needs further investigation. Incorporation of taxanes into adjuvant chemotherapy for early breast cancer is also controversial...
  12. ncbi Analysis of ipsilateral breast tumor recurrences after breast-conserving treatment based on the classification of true recurrences and new primary tumors
    Yoshifumi Komoike
    Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1 3 3 Nakamichi, Higashinari ku, Osaka 537 8511, Japan
    Breast Cancer 12:104-11. 2005
    ..The aim of this study is to clarify the biological difference between TR and NP, and to show the clinical significance of classifying IBTR into these two types of recurrence...
  13. ncbi [The evolving role of endocrine therapy for breast cancer]
    Hiromitsu Jinno
    Department of Surgery, Keio University School of Medicine
    Nippon Rinsho 64:547-54. 2006
    ....
  14. ncbi Randomized controlled trial comparing oral doxifluridine plus oral cyclophosphamide with doxifluridine alone in women with node-positive breast cancer after primary surgery
    Takeshi Tominaga
    Breast Cancer Center, Toyosu Hospital, Showa University School of Medicine, Tokyo, Japan
    J Clin Oncol 21:991-8. 2003
    ....
  15. ncbi Lymphoscintigraphy for the visualization of sentinel lymph nodes and body contour
    Hirofumi Fujii
    Department of Radiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Breast Cancer 11:250-5; discussion 264-6. 2004
    ..This clarity needs to reach a level where the sentinel lymph nodes (SLNs) and the body contour are clearly visible. We have developed a simple image processing method using the division of primary and scattered photon counts...
  16. ncbi Chemosensitivity-related genes of breast cancer detected by DNA microarray
    Tadashi Ikeda
    Department of Surgery, Keio University School of Medicine, Tokyo, Japan
    Anticancer Res 27:2649-55. 2007
    ..The feasibility of a preoperative docetaxel/5'-deoxy-5-fluorouridine (5'-DFUR) regimen for breast cancer patients was examined and the genes related to the response to it was investigated...
  17. ncbi [Current status of sentinel node adenectomy and future perspectives]
    Tadashi Ikeda
    Department of Surgery, Keio University Hospital, Tokyo, Japan
    Nippon Geka Gakkai Zasshi 105:480-4. 2004
    ..and a trial to detect lymphatic flow with CT after local injection of contrast medium is also being conducted. Sentinel node adenectomy may become a standard technique for early breast cancer patients in the near future...
  18. ncbi Identification of a new breast cancer-related gene by restriction landmark genomic scanning
    Sota Asaga
    Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, 160 8582, Japan
    Anticancer Res 26:35-42. 2006
    ..Although several prognostic markers have already been identified for breast cancer, it is clear that others remain to be identified...
  19. ncbi Evaluation of novel modified tangential irradiation technique for breast cancer patients using dose-volume histograms
    Atsuya Takeda
    Department of Radiology, Keio University School of Medicine and Tokyo Metropolitan Hiroo Hospita, Tokyo, Japan
    Int J Radiat Oncol Biol Phys 58:1280-8. 2004
    ....
  20. ncbi Sentinel lymph node biopsy in breast cancer using technetium-99m tin colloids of different sizes
    Hiromitsu Jinno
    Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160, Japan
    Biomed Pharmacother 56:213s-216s. 2002
    ..It was concluded that SLNB using the small-sized tin colloid was technically feasible and provided higher detection and identification rates than the regular-sized tin colloid...
  21. ncbi Emerging patterns of practice in the implementation and application of sentinel lymph node biopsy in breast cancer patients in Japan
    Tadashi Ikeda
    Department of Surgery, Keio University School of Medicine, Tokyo, Japan
    J Surg Oncol 84:173-5. 2003
  22. ncbi Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free interval
    Reiki Nishimura
    Department of Surgery, Kumamoto City Hospital, 1 1 60 Kotoh, Kumamoto 862 8505, Japan
    Anticancer Res 24:2085-91. 2004
    ..CONCLUSION: The good response rate and long TTP of this doxifluridine plus docetaxel regimen indicate its potential as a first- or second-line treatment for advanced/recurrent breast cancer patients...
  23. ncbi Prevention of mammary carcinogenesis in C3H/OuJ mice by green tea and tamoxifen
    Michio Sakata
    Department of Surgery, School of Medicine, Keio University, Tokyo, Japan
    Asian Pac J Cancer Prev 12:567-71. 2011
    ..In this study, we investigated their effects, alone or in combination, on mammary carcinogenesis using breast cancer cells and preneoplastic lesions inC3H/OuJ mice...
  24. ncbi ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3
    Yoko Mitsui
    Department of Pathology, School of Medicine, Keio University, Shinjuku ku, Tokyo, Japan
    Cancer Res 66:9913-20. 2006
    ....
  25. ncbi New challenges in the field of breast cancer therapy-do we need surgery for the patients with breast cancer?
    Tadashi Ikeda
    Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan
    Breast Cancer 14:37-8. 2007
  26. ncbi Efficacy of an MPC-BMA co-polymer as a nanotransporter for paclitaxel
    Masahiro Wada
    Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo 160 8582, Japan
    Anticancer Res 27:1431-5. 2007
    ..Paclitaxel (PTX) is administered as a solution in polyoxyethylated castor oil (CO) due to its low water solubility, but solvent-induced side-effects may be severe...
  27. ncbi Phase I study of docetaxel and cyclophosphamide in patients with advanced or recurrent breast cancer
    Tadao Shimizu
    Department of Surgery, Tokyo Women s Medical University Daini Hospital, 2 1 10 Nishiogu, Arakawa ku, Tokyo 116 8567, Japan
    Breast Cancer 10:140-8. 2003
    ....
  28. ncbi The cytotoxicity of a conjugate composed of human epidermal growth factor and eosinophil cationic protein
    Hiromitsu Jinno
    Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160, Japan
    Anticancer Res 22:4141-5. 2002
    ..CONCLUSION: Conjugates composed solely of human proteins might be useful with less immunogenicity and less toxicity than the conventional immunotoxins for targeted therapy...
  29. ncbi Outcomes of Japanese breast cancer patients treated with pre-operative and post-operative anastrozole or tamoxifen
    Yasuhiro Fujiwara
    National Cancer Center Hospital, Tokyo, Japan
    Cancer Sci 103:491-6. 2012
    ..Most patients responding to pre-operative therapy remained recurrence-free. Sequential pre-operative/post-operative treatment with anastrozole resulted in lower recurrence and death rates, compared with tamoxifen...
  30. ncbi The relationship between bone metastasis from human breast cancer and integrin alpha(v)beta3 expression
    Shin Takayama
    Department of Surgery, Keio University School of Medicine, 35 Shinanomachi, Shinjuku ku, Tokyo, Japan
    Anticancer Res 25:79-83. 2005
    ..Integrin alpha(v)beta3 mediates the attachment of osteoclasts to bone matrix, and it is overexpressed in bone-residing breast cancer cells. We studied BM from breast cancer in relation to its Integrin alpha(v)beta3 expression...
  31. ncbi Effects of toremifene and anastrozole on serum lipids and bone metabolism in postmenopausal females with estrogen receptor-positive breast cancer: the results of a 2-year multicenter open randomized study
    Keisei Anan
    Department of Surgery, Kitakyushu Municipal Medical Center, Fukuoka, Japan
    Breast Cancer Res Treat 128:775-81. 2011
    ..However, the serum BAP increase was not significant at 24 months. TOR provides better effects than ANA in terms of lipid profiles and bone metabolism in postmenopausal females with early breast cancer...
  32. ncbi [Intra-arterial infusion chemotherapy for breast cancer]
    Hideyuki Tokura
    Department of Surgery, Keio University Hospital, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan
    Gan To Kagaku Ryoho 29:176-81. 2002
    ..Accordingly, further studies including combined use of systemic chemotherapy are mandatory to the control of micrometastases outside the target organ...
  33. ncbi [Future directions of anticancer drug development in Japan]
    Hideyuki Akaza
    Urology, University of Tsukuba
    Gan To Kagaku Ryoho 35:351-60. 2008
    ..The number of Japanese patients necessary for Phase III studies is individual developmental strategy and needs to be examined by both companies and regulatory agencies...
  34. ncbi Predictive implications of nucleoside metabolizing enzymes in premenopausal women with node-positive primary breast cancer who were randomly assigned to receive tamoxifen alone or tamoxifen plus tegafur-uracil as adjuvant therapy
    Masakazu Toi
    Department of Surgery Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606 8507, Japan
    Int J Oncol 31:899-906. 2007
    ..After 2 years, the RPV of TS decreased with time, suggesting that 2 years of treatment with oral fluorouracil derivatives may be inadequate. Further studies are required to investigate this possibility...
  35. ncbi Long-term results of breast-conserving treatment for early-stage breast cancer in Japanese women from multicenter investigation
    Shozo Ohsumi
    National Shikoku Cancer Center, Matsuyama, Japan
    Jpn J Clin Oncol 33:61-7. 2003
    ..Although many clinical data regarding breast-conserving treatment have already been reported from European and North American countries, few clinical data with long-term follow-up have been reported from Japan...
  36. ncbi [Globalization of clinical trials]
    Hideyuki Akaza
    Dept. of Urology, Institute of Clinical Medicine, University of Tsukuba
    Gan To Kagaku Ryoho 30:555-65. 2003
    ..If we can address these issues Japanese investigators and collaborative groups should be able to initiate and lead global trials in the future...
  37. ncbi [Present status and future perspective of surgical therapy for breast neoplasms]
    Tadashi Ikeda
    Department of Surgery, Teikyo University School of Medicine
    Nippon Rinsho 65:434-8. 2007
  38. ncbi Dofequidar fumarate (MS-209) in combination with cyclophosphamide, doxorubicin, and fluorouracil for patients with advanced or recurrent breast cancer
    Toshiaki Saeki
    National Shikoku Cancer Center, Matsuyama, Japan
    J Clin Oncol 25:411-7. 2007
    ..Dofequidar is a novel, orally active quinoline derivative that reverses multidrug resistance...
  39. ncbi 1-hexylcarbamoyl-5-fluorouracil + cyclophosphamide + tamoxifen versus CMF + tamoxifen in women with lymph node-positive breast cancer after primary surgery: a randomized controlled trial
    Takeshi Tominaga
    Breast Cancer Center, Toyosu Hospital, Showa University School of Medicine, Tokyo 135 8577, Japan
    Oncol Rep 12:797-803. 2004
    ..Study results suggest that 2-year HCT therapy including the oral 5-FU anti-cancer drug HCFU is a useful adjuvant therapy which can replace CMFT therapy in early breast cancer cases with 3 or lower metastatic lymph nodes...
  40. ncbi Inhibition of bone metastasis from breast cancer with pamidronate resulting in reduction of urinary pyridinoline and deoxypyridinoline in a rat model
    Noriaki Wada
    Division of Breast Surgery, National Cancer Center Hospital East, 6 5 1 Kashiwanoha Kashiwa Chiba, 277 8577, Japan
    Breast Cancer 11:282-7. 2004
    ....
  41. ncbi [Developments in endocrine therapy for breast cancer]
    Akira Matsui
    Keio Cancer Center, Keio University Hospital
    Gan To Kagaku Ryoho 29:1138-45. 2002
    ..Currently, many clinical randomized trials are being conducted to examine the effectiveness of new endocrine treatment. Significant changes are occurring in the endocrine treatment of breast cancer...
  42. ncbi Impact of left atrial volume reduction concomitant with atrial fibrillation surgery on left atrial geometry and mechanical function
    Akira Marui
    Department of Cardiovascular Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
    J Thorac Cardiovasc Surg 135:1297-305. 2008
    ..We sought to investigate the perioperative factors that influence left atrial geometry and mechanical functions after the Maze procedure in patients with refractory atrial fibrillation and left atrial enlargement...
  43. ncbi [Globalization of anti-cancer therapies]
    Hideyuki Akaza
    Dept. of Urology, Institute of Clinical Medicine, University of Tsukuba
    Gan To Kagaku Ryoho 29:205-14. 2002
    ..There have been some recent improvements and further progress is expected so that Japanese doctors can play a full role in the evaluation of new therapies...
  44. ncbi Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial
    Masafumi Kurosumi
    Saitama Cancer Center, 818 Komuro, Ina machi, Kitaadachi gun, Saitama 362 0806, Japan
    J Cancer Res Clin Oncol 134:715-22. 2008
    ....
  45. ncbi [Post launch studies]
    Hideyuki Akaza
    Dept. of Urology, Institute of Clinical Medicine, University of Tsukuba, Japan
    Gan To Kagaku Ryoho 29:2037-48. 2002
    ..In fact, researcher-initiated clinical trials achieved a rapid growth in Japan in the past year...
  46. ncbi Early and mid-term results of left ventricular volume reduction surgery for dilated cardiomyopathy
    Tadaaki Koyama
    Department of Cardiovascular Surgery, Kyoto University, Graduate School of Medicine, Sakyo-ku Kyoto, Japan
    J Card Surg 20:S39-42. 2005
    ..8% and 93.8%, respectively (p = 0.099). CONCLUSIONS: Early and mid-term results of LVVRS were satisfied, and the non-Dor operation tended to be superior in mid-term survival to the Dor operation. Long-term follow-up is warranted...
  47. ncbi Invasive lobular carcinoma arising in phyllodes tumor of the breast
    Takahide Kodama
    Virchows Arch 442:614-6. 2003
  48. ncbi Antitumor effect of combination of S-1 and docetaxel on the human breast cancer xenograft transplanted into SCID mice
    Akihiko Suto
    Department of Surgery Yamato Municipal Hospital, 8 3 6 Fukami nishi, Yamato City Kanagawa 242 8602, Japan
    Oncol Rep 15:1517-22. 2006
    ..Down-regulation of the DPD activity of the tumors is also considered to be correlated with the antitumor effect of the treated groups, suggesting its influence on the synergistic effect of the combination therapy...
  49. ncbi To overcome breast cancer with all of our knowledge
    Tadashi Ikeda
    Breast Cancer 15:8-9. 2008